Perceptive Advisors - Q3 2021 holdings

$6.88 Billion is the total value of Perceptive Advisors's 139 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 100.0% .

 Value Shares↓ Weighting
RAPT ExitRAPT THERAPEUTICS INCput$0-90,000
-100.0%
-0.00%
TCRR ExitTCR2 THERAPEUTICS INC$0-61,506
-100.0%
-0.01%
TKNO ExitALPHA TEKNOVA INC$0-60,000
-100.0%
-0.01%
PLXP ExitPLX PHARMA INC$0-114,918
-100.0%
-0.01%
SCPEWS ExitSC HEALTH CORP*w exp 99/99/999$0-1,000,000
-100.0%
-0.01%
SGTX ExitSIGILON THERAPEUTICS INC$0-250,000
-100.0%
-0.02%
SRRA ExitSIERRA ONCOLOGY INC$0-133,310
-100.0%
-0.02%
CEREW ExitCEREVEL THERAPEUTICS HLDNG I*w exp 06/09/202$0-266,132
-100.0%
-0.02%
GRTX ExitGALERA THERAPEUTICS INC$0-509,328
-100.0%
-0.03%
CMLF ExitCM LIFE SCIENCES INC$0-454,000
-100.0%
-0.04%
AMWL ExitAMERICAN WELL CORPcl a$0-580,000
-100.0%
-0.05%
MRUS ExitMERUS NV$0-350,000
-100.0%
-0.05%
LGVU ExitLONGVIEW ACQUISITION CORP IIunit 99/99/9999$0-1,000,000
-100.0%
-0.06%
CHFWU ExitCONSONANCE HFW ACQUISITION Cunit 99/99/9999$0-1,000,000
-100.0%
-0.07%
MREO ExitMEREO BIOPHARMA GROUP PLCads$0-3,392,136
-100.0%
-0.07%
BCTG ExitBCTG ACQUISITION CORP$0-1,000,000
-100.0%
-0.07%
AKYA ExitAKOYA BIOSCIENCES INC$0-600,000
-100.0%
-0.08%
PRVA ExitPRIVIA HEALTH GROUP INC$0-270,000
-100.0%
-0.08%
SILK ExitSILK RD MED INC$0-294,266
-100.0%
-0.09%
RACA ExitTHERAPEUTICS ACQUISITION COR$0-1,500,000
-100.0%
-0.10%
CTMX ExitCYTOMX THERAPEUTICS INC$0-3,281,914
-100.0%
-0.14%
CVRX ExitCVRX INC$0-880,000
-100.0%
-0.16%
ExitCATABASIS PHARMACEUTICALS IN$0-15,374,370
-100.0%
-0.21%
TDOC ExitTELADOC HEALTH INCcall$0-200,000
-100.0%
-0.22%
CMIIU ExitCM LIFE SCIENCES II INCunit 02/25/2028$0-2,500,000
-100.0%
-0.22%
STOK ExitSTOKE THERAPEUTICS INC$0-1,343,956
-100.0%
-0.29%
FBRX ExitFORTE BIOSCIENCES INC$0-1,370,000
-100.0%
-0.30%
COLL ExitCOLLEGIUM PHARMACEUTICAL INC$0-1,956,554
-100.0%
-0.30%
ARWR ExitARROWHEAD PHARMACEUTICALS IN$0-630,282
-100.0%
-0.34%
RGEN ExitREPLIGEN CORP$0-265,000
-100.0%
-0.34%
XLRN ExitACCELERON PHARMA INC$0-453,520
-100.0%
-0.37%
NARI ExitINARI MED INC$0-620,874
-100.0%
-0.38%
EXAS ExitEXACT SCIENCES CORP$0-467,046
-100.0%
-0.38%
DRNA ExitDICERNA PHARMACEUTICALS INC$0-1,600,000
-100.0%
-0.39%
MDT ExitMEDTRONIC PLC$0-900,000
-100.0%
-0.73%
KDMN ExitKADMON HLDGS INC$0-31,422,668
-100.0%
-0.79%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR/A filed 2021-12-03
Signatures

The EDGAR filing(s) were signed by:

About Perceptive Advisors

Perceptive Advisors is a New York-based hedge fund that specializes in healthcare investments. The company was founded in 1999 by Joseph Edelman, who serves as the CEO and Chief Investment Officer. Since its inception, Perceptive Advisors has become one of the most successful healthcare-focused hedge funds in the world, with over $5 billion in assets under management.

The company's investment strategy is based on a deep understanding of the healthcare industry and a focus on identifying promising companies with innovative products and technologies. Perceptive Advisors invests in a wide range of healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services.

One of the key factors behind Perceptive Advisors' success is its team of experienced professionals. In addition to Joseph Edelman, the company's leadership team includes Adam Stone, the COO, and Jeremy Goldberg, the Chief Scientific Officer. The team also includes a group of highly skilled analysts and researchers who are experts in their respective fields.

Perceptive Advisors has a strong track record of generating high returns for its investors. However, it is important to note that investing in hedge funds carries significant risks, and investors should carefully consider their investment objectives and risk tolerance before investing. As with any investment, it is important to conduct thorough research and seek the advice of a qualified financial advisor before making any investment decisions.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES SHARES42Q3 202315.7%
AMICUS THERAPEUTICS SHARES39Q3 202314.0%
ALDEYRA THERAPEUTICS SHARES35Q3 20233.3%
QUOTIENT TECHNOLOGY INC34Q3 20222.7%
GLOBAL BLOOD THERAPEUTICS SHARES29Q3 20229.3%
ADMA BIOLOGICS SHARES29Q3 20231.4%
RETROPHIN SHARES28Q3 20205.5%
DBV TECHNOLOGIES SA-SPON ADR28Q3 20211.8%
VBI VACCINES SHARES27Q1 20232.8%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%

View Perceptive Advisors's complete holdings history.

Latest significant ownerships (13-D/G)
Perceptive Advisors Q3 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
CHEMBIO DIAGNOSTICS, INC.Sold outMay 04, 202300.0%
VBI Vaccines Inc/BCApril 07, 202343,509,55316.7%
Landos Biopharma, Inc.March 30, 202314,869,91547.7%
REATA PHARMACEUTICALS INCMarch 07, 20232,083,7996.5%
AGILE THERAPEUTICS INCSold outFebruary 14, 202300.0%
ALBIREO PHARMA, INC.February 14, 20231,757,1608.5%
BELLUS Health Inc.February 14, 20238,891,0277.1%
CinCor Pharma, Inc.February 14, 20232,576,3255.9%
Coherus BioSciences, Inc.Sold outFebruary 14, 202300.0%
CONCERT PHARMACEUTICALS, INC.February 14, 20231,800,0003.6%

View Perceptive Advisors's complete significant-ownership history.

Latest filings
TypeFiled
SC 13D2024-03-20
SC 13G2024-03-14
SC 13G2024-03-11
SC 13G/A2024-03-06
SC 13D/A2024-03-01
SC 13G2024-03-01
SC 13D/A2024-02-29
13F-HR/A2024-02-26
SC 13G/A2024-02-23
42024-02-21

View Perceptive Advisors's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported number of holdings is incorrect (139 != 140)
  • The reported has been restated
  • The reported has been amended

Export Perceptive Advisors's holdings